Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

NCT04066790 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

12

Enrollment

OTHER

Sponsor class

Stopped We terminated this trial and initiated a new one including pertuzumab.

Conditions

Breast Cancer

Interventions

DRUG: Pyrotinib
DRUG: nab-Paclitaxel
DRUG: Trastuzumab
DRUG: EC chemotherapy
PROCEDURE: Surgery

Sponsor

Shanghai Jiao Tong University School of Medicine

Collaborators

[object Object]